Eli Lilly and Co.'s (NYSE:LLY) Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) Wegovy (semaglutide) for market dominance.

According to a GlobalData report, Zepbound's superior effectiveness and strategic market growth position it to potentially overtake Wegovy as the leading therapy for obesity.

Since its debut, Zepbound has expanded its scope beyond obesity treatment. In December 2024, the FDA approved the drug for treating obstructive sleep apnea.

Ongoing studies are exploring additional indications, such as reducing cardiovascular risks, addressing chronic kidney disease, and treating metabolic dysfunction-associated steatohepatitis (MASH).

Also Read: Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services.

GlobalData's Pharma Analyst, Costanza Alciati, highlighted that Eli Lilly is emulating Novo Nordisk's approach by exploring multiple therapeutic areas to broaden Zepbound's market potential.

Wegovy has been a game-changer in the obesity sector, earning widespread recognition and driving significant investment in the field. Over 400 companies are now developing obesity therapies inspired by Wegovy's success. The drug is also approved for managing type 2 diabetes and cardiovascular risks, with further research focusing on conditions like chronic kidney disease.

Despite Wegovy's achievements, Alciati remarked that Zepbound is "raising the bar" with greater potency and potential cost-effectiveness, making it a formidable contender in the obesity market.

In parallel, healthcare costs in the U.S. are climbing rapidly. Aon plc's (NYSE:AON) August report projects a 9% increase in employer-sponsored healthcare costs for 2025, exceeding $16,000 per employee.

This surge surpasses the 6.4% rise from 2023 to 2024, driven by higher medical claims, rising prescription drug expenses, and inflation-related adjustments.

Specialty drugs, particularly GLP-1 medications like tirzepatide and semaglutide, are key drivers of these rising costs. Aon's analysis reveals that these medications could add 1% to overall healthcare cost increases.

Despite their low utilization, these therapies significantly impact employer healthcare budgets.

On average, U.S. employers cover 81% of health plan costs, leaving employees to pay 19%, amounting to $4,858 annually, including premiums and out-of-pocket expenses.

In 2024, employer healthcare budgets grew by 6.4%, while employee premiums increased by a more modest 3.4%, according to Aon's analysis.

The technology and communications sector experienced the highest employer cost increase at 7.4% in 2024, while public sector employees faced the steepest rise in contributions at 6.7%.

In contrast, the healthcare industry saw no material change in employee contributions.

High-cost claims stemming from gene and cell therapies, complex medical procedures, and chronic conditions further strain employer budgets.

Price Action: LLY stock is up 0.88% at $778.79 during the premarket session at the last check on Thursday.

Read Next:

• Arcos Dorados Renews Franchise Agreement With McDonald's, Stock Gains

Photo by Ciara Kimsey via Shutterstock

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.

Get the latest stock analysis from Benzinga?

• NOVO NORDISK (NVO): Free Stock Analysis Report
• ELI LILLY (LLY): Free Stock Analysis Report

This article US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report originally appeared on Benzinga.com

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.